CN115428952A - 预防与改善微循环障碍相关疾病的组合物、其制法及应用 - Google Patents
预防与改善微循环障碍相关疾病的组合物、其制法及应用 Download PDFInfo
- Publication number
- CN115428952A CN115428952A CN202211179904.6A CN202211179904A CN115428952A CN 115428952 A CN115428952 A CN 115428952A CN 202211179904 A CN202211179904 A CN 202211179904A CN 115428952 A CN115428952 A CN 115428952A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- powder
- composition
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 50
- 201000010099 disease Diseases 0.000 title claims abstract description 44
- 230000004089 microcirculation Effects 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 149
- 240000000249 Morus alba Species 0.000 claims abstract description 61
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 61
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 48
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 35
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 35
- 239000002994 raw material Substances 0.000 claims abstract description 33
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 27
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 27
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 27
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 27
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 27
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 24
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 24
- 241000208688 Eucommia Species 0.000 claims abstract description 23
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 20
- 244000237330 gutta percha tree Species 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims description 107
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 62
- 238000007873 sieving Methods 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 42
- 235000008434 ginseng Nutrition 0.000 claims description 39
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 37
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 37
- 238000001035 drying Methods 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 37
- 238000010298 pulverizing process Methods 0.000 claims description 29
- 238000001914 filtration Methods 0.000 claims description 25
- 241000243684 Lumbricus Species 0.000 claims description 21
- 235000019441 ethanol Nutrition 0.000 claims description 17
- 206010034568 Peripheral coldness Diseases 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000008055 phosphate buffer solution Substances 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 150000004676 glycans Chemical class 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 208000006820 Arthralgia Diseases 0.000 claims description 8
- 206010033557 Palpitations Diseases 0.000 claims description 8
- 208000034783 hypoesthesia Diseases 0.000 claims description 8
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 7
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 7
- 206010008479 Chest Pain Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 7
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 7
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 7
- 229940074393 chlorogenic acid Drugs 0.000 claims description 7
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 7
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 7
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 208000002173 dizziness Diseases 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 231100000869 headache Toxicity 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 201000006549 dyspepsia Diseases 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 229930182494 ginsenoside Natural products 0.000 claims description 5
- 229940089161 ginsenoside Drugs 0.000 claims description 5
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 4
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 4
- 208000032912 Local swelling Diseases 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 240000004371 Panax ginseng Species 0.000 claims 6
- 235000002789 Panax ginseng Nutrition 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- 230000001603 reducing effect Effects 0.000 abstract description 15
- 230000036039 immunity Effects 0.000 abstract description 12
- 230000003647 oxidation Effects 0.000 abstract description 8
- 238000007254 oxidation reaction Methods 0.000 abstract description 8
- 210000004204 blood vessel Anatomy 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 210000002889 endothelial cell Anatomy 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 description 33
- 230000000694 effects Effects 0.000 description 27
- 230000006870 function Effects 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000010729 leg swelling Diseases 0.000 description 5
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000237637 Megascolecidae Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 210000003989 endothelium vascular Anatomy 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- -1 oxygen free radical Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 241001233061 earthworms Species 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 description 1
- ZJSJQWDXAYNLNS-FUPWJLLWSA-N (2s,3r,4s,5s,6r)-2-[4-[(3s,3ar,6s,6ar)-6-[3-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound COC1=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)CO2)=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZJSJQWDXAYNLNS-FUPWJLLWSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000032028 Microvascular Rarefaction Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101710170789 Protein bax Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000376 effect on fatigue Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000008799 immune stress Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 150000003244 quercetin derivatives Chemical class 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000018648 unbalanced nutrition Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种预防与改善微循环障碍相关疾病的组合物、其制法及应用,所述的组合物包括如下原料组分:地龙提取物30‑50份、枸杞子提取物4‑12份、人参提取物10‑20份、杜仲叶提取物8‑20份、桑叶提取物7‑11份、葛根提取物7‑21份。本发明所述的组合物,通过采用地龙提取物、枸杞子提取物、人参提取物、杜仲叶提取物、桑叶提取物、葛根提取物为原料并进行适合的重量配比,使得各组分协同作用,从维持血管内张力和结构,修复损伤的内皮细胞,减少炎症介质释放,调节血液流变性,抗氧化以及增强免疫等多个方面共同作用,可较好的控制引起微循环障碍的多种危险因素,有效预防与改善微循环障碍相关疾病。
Description
技术领域
本发明属于食品技术领域,具体涉及一种预防与改善微循环障碍相关疾病的组合物、其制法及应用。
背景技术
微循环是沟通全身组织细胞和保证血流量的重要通道,且与组织细胞直接接触进行物质交换,向各组织细胞运输营养物质,带走代谢产物。当微循环发生障碍时,如淋巴和血管腔狭窄、血流减速或形成血栓,就会导致局部组织因缺血缺氧而坏死,因而引起机体衰老、免疫功能失调及疾病的发生。微循环障碍几乎与各个系统疾病都存在着密切关系,好发于脑中风、冠心病、糖尿病、高血压、急性胰腺炎、突发性耳聋等疾病。现代生活中人们不合理、高热量、过度过量等不健康的饮食习惯,导致人体营养不均衡,进而引发血脂异常。当人体有血脂异常症发生时,血液内成分比例出现失调,血液粘稠度升高,血液循环流经动脉毛细血管处时,流速必然减缓,当血流驱动力不足以克服血流阻力时,自然发展为流不动而逐步形成阻塞,造成了我们体内的微循环障碍。随着年龄的增加,机体机能的退化,毛细血管迂曲、扭转程度增加,老年人尤其70岁以后,毛细血管急剧迂曲,毛细血管呈多角形、筛网状分布,呈现出动脉系统逐渐硬化、静脉系统逐渐瘀滞、血流逐渐缓慢的微循环障碍形态及流态。因此,控制引起微循环障碍的危险因素,降低微循环障碍的发生风险与危害,是至关重要的。
微循环障碍往往在疾病发生的早期出现,甚至在疾病尚未出现任何症状前,微循环就已经出现不同程度的功能障碍或结构障碍。在炎症反应、代谢障碍等病理情况下,可出现微血管结构和毛细血管密度的异常改变,进而引发微循环障碍,通常微循环障碍分为结构障碍和功能障碍两大类。微循环结构障碍主要表现为微血管密度下降、微血管畸形、管壁增厚以及管腔狭窄等。微循环功能障碍是指微血管的血流灌注量减少或无灌注。内皮是血液和血管之间有选择的渗透屏障,可以维持血管张力和结构,且具有自我调节功能。血管内皮结构正常是维持微循环功能的前提,血管内皮主要是产生松弛因子一氧化氮,一氧化氮的底物L-精氨酸在维持血管内皮功能中有重要作用。过多的活性氧类可以抑制一氧化氮的活性,使血管壁依赖的一氧化氮免疫保护功能(抑制血小板的黏附和聚集,白细胞黏附和迁移,平滑肌细胞的增殖等)受损,从而损伤血管内皮。炎症因子(白细胞介素、C反应蛋白、肿瘤坏死因子等)水平升高也可导致血管内皮功能障碍,进而引发微循环障碍。小动脉和微动脉中胶原蛋白(尤其是胶原蛋白Ⅲ型)的增加可以诱发微血管结构的改变,且可溶性内皮糖蛋白与毛细血管稀疏之间的特异性分级紧密相关。目前治疗微循环障碍的产品多集中在药物上,用于改善微循环障碍引起的相关疾病,忽略了出现疾病前引起微循环不同程度的功能障碍与结构障碍的因素,如高血压、高血脂、高血糖、炎症因子与氧化应激等。
发明内容
本发明的目的在于提供一种预防与改善微循环障碍相关疾病的组合物、其制法及应用,所述的组合物通过采用地龙提取物、枸杞子提取物、人参提取物、杜仲叶提取物、桑叶提取物、葛根提取物为原料并进行适合的重量配比,使得各组分协同作用,从维持血管内张力和结构,修复损伤的内皮细胞,减少炎症介质释放,调节血液流变性,抗氧化以及增强免疫等多个方面共同作用,可较好的控制引起微循环障碍的多种危险因素,有效预防与改善微循环障碍相关疾病。
为实现本发明的上述目的,本发明采用以下技术方案:
本发明提供一种预防与改善微循环障碍相关疾病的组合物,包括如下原料组分:地龙提取物30-50份、枸杞子提取物4-12份、人参提取物10-20份、杜仲叶提取物8-20份、桑叶提取物7-11份、葛根提取物7-21份。
优选的,所述预防与改善微循环障碍相关疾病的组合物,包括如下原料组分:地龙提取物35-45份、枸杞子提取物6-10份、人参提取物12-16份、杜仲叶提取物10-16份、桑叶提取物8-10份、葛根提取物13-19份。
优选的,所述预防与改善微循环障碍相关疾病的组合物,包括如下原料组分:地龙提取物40份、枸杞子提取物8份、人参提取物14份、杜仲叶提取物12份、桑叶提取物9份、葛根提取物17份。
优选的,所述地龙提取物的蛋白含量不低于26%;所述人参提取物的人参皂苷含量为2.5-3%、多糖含量为10-12%;所述杜仲叶提取物的绿原酸含量为3.9-4.2%;所述葛根提取物的葛根素含量为10-12%。
优选的,所述地龙提取物按如下方法制备得到:取地龙,依次经干燥、粉碎、过筛后,得地龙粉;向地龙粉中加入pH6.8的磷酸盐缓冲液,所述的地龙粉与磷酸盐缓冲液的重量比为1:10-20,于4℃冷浸12-14h,过滤,滤液中加入无水乙醇,滤液与无水乙醇的体积比为1:3,于4℃静置12h,过滤,滤渣干燥后,即得。
优选的,所述枸杞子提取物、人参提取物、桑叶提取物、葛根提取物分别为枸杞子、人参、桑叶以及葛根的水提取物,所述的杜仲叶提取物为杜仲叶的醇提取物。
优选的,所述枸杞子提取物按如下方法制备得到:取枸杞子,依次经干燥、粉碎、过筛后,得枸杞子粉;向枸杞子粉中加入水,所述的枸杞子粉与水的重量比为1:30-40,80℃提取40-60min,得提取液;将提取液过滤,滤液浓缩至相对密度为0.8-1.1,得浓缩液;向浓缩液中加入无水乙醇,所述的浓缩液与无水乙醇的体积比为1:3-5,于4℃静置12h,过滤取上清,经冷冻干燥、过筛后,即得;
和/或,所述人参提取物按如下方法制备得到:取人参,依次经干燥、粉碎、过筛后,得人参粉;向人参粉中加入水,所述的人参粉与水的重量比为1:15-20,然后于沸水浴中提取1-2h,得提取液,经过滤、浓缩、冷冻干燥、过筛后,即得;
和/或,所述杜仲叶提取物按如下方法制备得到:取杜仲叶,依次经干燥、粉碎、过筛后,得杜仲叶粉;向杜仲叶粉中加入浓度为50%v/v的乙醇,所述的杜仲叶粉与乙醇的重量比为1:10-12,然后于80-90℃提取1-2h,得提取液,经过滤、浓缩、冷冻干燥、过筛后,即得;
和/或,所述桑叶提取物按如下方法制备得到:取新鲜桑叶,依次经干燥、粉碎、过筛后,得桑叶粉;向桑叶粉中加入水,所述的桑叶粉与水的重量比为1:10-15,然后60℃超声波提取0.5-1h,得提取液,经过滤、浓缩、冷冻干燥、过筛后,即得;
和/或,所述葛根提取物按如下方法制备得到:取葛根,依次经清洗、破碎后,得葛根粗粒;向葛根粗粒中加入水,所述的葛根粗粒与水的重量比为1:30-40,然后于沸水浴中提取1-2h,得提取液,经过滤、浓缩、喷雾干燥、过筛后,即得。
本发明提供的组合物,各原料作用详述如下:
地龙,为钜蚓科动物参环毛蚓、通俗环毛蚓、威廉环毛蚓或栉盲环毛蚓的干燥体。始记于《神农本草经》,在我国已有悠久的使用历史。其性寒,味咸,归肝、脾、膀胱经,具有清热止痉、平肝熄风、通经活络、平喘利尿的功效;用于治疗高热神昏、惊痫抽搐、关节痹痛、肺热喘咳、尿少水肿、高血压等症。蚯蚓体内的蛋白质成分含量较大,干体地龙中蛋白质的含量高达60%左右,其蛋白质含量约为豆类产品蛋白质含量的1.5倍,为谷类食品蛋白质(Pr)含量的6倍左右,其中蛋白多肽类成分质量分数高达55%~68%,具有抗凝血、降压、抗菌、抗脑卒中、神经保护等多方面的药理作用。地龙中含有的氨基酸种类,含量最高的氨基酸为谷氨酸和亮氨酸,其次含量较高的氨基酸为赖氨酸、丙氨酸、精氨酸、天冬氨酸、缬氨酸,这八种氨基酸也是人体必需的氨基酸。地龙含有的脂类成分主要为磷脂、不饱和脂肪酸、硬脂酸、胆淄醇和棕榈酸等,除此之外,蚯蚓中含有一些较为重要的构成核苷酸的成分,在人体的核酸代谢中,核苷酸是至关重要的原料之一。地龙中含有较为丰富的过氧化氢酶、纤溶酶以及卟啉合成酶等,主要的微量元素有钼、镁、铜、锌、锶、硒、钴和镍等,人体维持自身的健康状态都需要这些微量元素,这也是根本保障物质。地龙的水提液能够明显延长机体内的纤维蛋白血栓和血小板血栓的形成时间,显著减少血栓的干重以及长度。激酶和纤溶酶共同对血液产生作用,纤维蛋白原在血液中的含量明显较少,稀释血液,改善血液粘稠度。
枸杞,是传统的药食兼用型中药,主要营养成分及活性物质有枸杞多糖、甜菜碱、类胡萝卜素、枸杞黄酮、蛋白质及17种氨基酸等,可以发挥营养调控和保健的功效。枸杞口感甘甜,具有增强免疫、抗氧化、抗肿瘤、降血糖、降血脂、调节和保护神经、视觉、生殖系统的功能。枸杞多糖能刺激机体产生多种淋巴细胞因子,在体内促进免疫活性细胞的分裂增殖,提高巨噬细胞的吞噬作用及T淋巴细胞的杀伤力。枸杞多糖能够增加机体中糖原储备量,加快自由基、乳酸等的清除,对疲劳有一定的缓解作用。清除体内氧自由基及其代谢产物,提高抗氧化能力,改善机体过氧化损伤,具有一定延缓衰老的作用。枸杞多糖能通过内质网促进蛋白质的合成,具有解毒作用,可恢复肝细胞的功能,促进肝细胞再生,对某些原因引起的肝损伤有良好的修复作用。枸杞多糖还可增加神经损伤的大鼠血清超氧化物歧化酶和谷胱甘肽过氧化物酶活性,减少氧化应激,减少神经元损伤,促进神经再生和功能恢复;抑制小鼠脑缺血再灌注损伤后促凋亡蛋白Bax的表达,促进抗凋亡蛋白Bcl-2的表达,抑制神经元的过度凋亡,对缺血侧脑组织具有神经保护作用。枸杞多糖可显著降低高脂膳食小鼠体内血脂、血糖和高密度脂蛋白水平,降低体内氧化应激水平,还可保护2型糖尿病大鼠的胰岛β细胞,降低血糖和血脂浓度。甜菜碱可以维持细胞渗透压,是机体良好的渗透调节剂,低浓度的甜菜碱可以抵抗无机渗透调节剂对酶活性和代谢过程的毒害,同时对能量代谢和有氧呼吸也有直接的保护作用。甜菜碱在机体内能迅速合成积累以减少水分流失,并维持蛋白质和生物膜正常的结构和功能。
人参,之名始载于《神农本草经》,谓“人参,味甘,微寒,主补五脏,安精神,定魂魄,止惊悸,除邪气,明目,开心益智,久服轻身延年”。人参化学成分复杂,包括人参皂苷、人参多糖、挥发油、氨基酸、多肽、蛋白质、多种维生素、有机酸、生物碱、脂肪类、黄酮类、酶类、甾醇、核苷、木质素、无机元素等多种成分。人参的主要成分是人参皂苷,人参皂苷主要有以下种类:Rh2:抑制癌细胞扩散,增强免疫力,促进伤口愈合;Rg:抗疲劳、兴奋,益智、提高记忆功能;Rg1:抗缓衰老,兴奋中枢神经系统;Rg2:防治心肌缺血、缺氧和冠心病;Rg3:抗肿瘤细胞的扩散和转移、加速肿瘤细胞的衰亡;Rb1:具有增强胆碱系统的功能;Rb2:促进DNA、RNA的合成,清除体内过氧化的自由基;Rb3:提高人体免疫力,保护心肌系统;Rh:镇定、安神、抑制兴奋;Rh1:防治肝炎、肝硬化;Ro:消炎、解毒、抗血栓。人参多糖可刺激免疫功能,对体液免疫及细胞免疫、特异性免疫及非特异性免疫均有影响。同时,人参多糖能明显抑制炎症状态下的巨噬细胞过度表达炎症因子IL-1β、TNF-α,从而减轻免疫应激反应,进而减轻组织损伤。人参多糖可以显著增加骨关节炎大鼠血清中超氧化物歧化酶的活性,发挥抗氧化作用。
杜仲,具有补肝肾,强筋骨,安胎和降压等作用,主治腰膝痛,除阴下痒湿等,《本草纲目》中记述的杜仲功效是“补中,益精气,坚筋骨,强志,久服,轻身耐老”,并将其列为“上品”。现代研究表明,杜仲具有显著的抗菌、消炎、抗氧化、抗肿瘤及增强免疫等作用。杜仲叶的活性成分集中于木质素类、环烯醚萜类、类苯丙素、黄酮类化合物等。此外,杜仲叶还具有多种营养要素,如氨基酸、矿物质、胡萝卜素、脂肪等。杜仲叶中的绿原酸及其衍生物具有显著的抗菌、抗病毒和抗炎作用,并能显著提高白细胞数量。杜仲叶中的绿原酸有类似于肾上腺素的作用,通过抑制病原体的侵入预防疾病,提高动物自身的免疫力。杜仲叶提取物可以抑制脂肪的吸收转化以及抑制肠道吸收、肝胆固醇生物合成,从而达到降血脂的作用。杜仲叶对血压具有双向调节作用,其降压效果尤为明显,主要有效成分为木脂素类化合物松脂醇二葡萄糖苷,且水煎液的降压作用比醇提液强,杜仲叶较杜仲皮具有更佳的疗效,已作为医用降压药。
桑叶,始载于《神农本草经》,味苦、甘,性寒,归肺、肝经;功能疏散风热、清肺润燥、清肝明目;含有丰富的氨基酸、维生素、矿物质、纤维素以及多种生理活性物质。桑叶的组分1-脱氧野尻霉素从胃肠黏膜吸收,迅速扩散到肝,能够抑制α-糖苷酶的活性阻碍蔗糖和麦芽糖等二糖与α-糖苷酶的结合从而减少进入血液中的葡萄糖,降低了血糖值。另外,桑叶所含绿原酸、芦丁、异槲皮苷、多糖、黄酮类和相关化合物,也能发挥抗糖尿病活性。桑叶有效的降低了血清胆固醇、甘油三酯、低密度脂蛋白,具有降血脂作用,有效地抑制细胞增殖和血管平滑肌细胞的迁移,减轻动脉粥样硬化负担。桑叶的槲皮素衍生物可通过降低氧化应激和促进脂肪酸β氧化直接改善的脂质和葡萄糖代谢。桑叶含有的抗氧化黄酮类化合物具有清除自由基的作用,能够减轻心脏氧化应激和心脏起搏引起的充血性心脏衰竭的心脏功能障碍。
葛根,是我国传统的药食同源中药材,具有解肌退热、透疹、生津止渴、升阳止泻等功效。葛根富含多种化学成分,主要有异黄酮类、三萜类、皂苷类、生物碱类、香豆素类化合物和多糖类,其中异黄酮类和三萜类化合物为主要的药理活性成分。现代药理研究表明,葛根具有改善心脑血管疾病、抗糖尿病、抗肿瘤、抗病毒、抗炎、抗自由基、预防骨质疏松、保护肝脏、调节免疫、解酒、解热等多种药理作用。血管内皮依赖性舒张和收缩失衡也会导致血压的升高,大豆苷和大豆苷元可以通过调控K+通道的开放和抑制血管平滑肌细胞内Ca2+内流影响血管舒张;葛根素通过NO产生的内皮依赖机制和K+通道介导的内皮通路促进血管舒张;进而改善高血压。葛根通过通过调节血脂,抑制颈动脉内原中膜增厚,减少粥样硬化斑块形成,减轻炎症反应,从而发挥抗动脉粥样硬化的作用。根中异黄酮类自身的抗氧化能力较强,能够抑制酪氨酸酶活性,有效的清除机体氧自由基物质,平衡高脂膳食引起的氧化应激,避免生物膜氧化损伤以及自由基对DNA造成的损伤。
本发明所述预防与改善微循环障碍相关疾病的组合物的制备方法,具体步骤为:分别取各原料,将所述各原料混合均匀,即得。
本发明所述预防与改善微循环障碍相关疾病的组合物在制备预防与改善微循环障碍相关疾病的保健食品或药品中的应用,所述微循环障碍相关疾病的症状包括头晕、头痛、失眠、胸闷、心慌、腰酸、手脚冰凉、四肢麻木、腿部肿胀、消化不良、关节痛中的任意一种或几种。
本发明的有益效果为:
1、本发明提供的组合物,1)地龙提取物、杜仲叶提取物、葛根提取物共同作用,可促进内皮细胞释放NO,改善血管舒张;抑制血管紧张素Ⅱ的生成,扩张血管,增加血流量;促进血管平滑肌收缩,改善血管舒张和收缩功能;进而提高血管血流速度,改善头晕、头痛、肢体麻木等症状;2)地龙提取物中的地龙蛋白、枸杞子提取物中的枸杞多糖与黄酮、桑叶提取物中的黄酮类物质共同作用,能够抑制血小板聚集,稀释血液,改善血液粘度;调节脂类与糖类代谢,降低血脂与血糖减少对内皮细胞的损伤;降低促炎性细胞因子的表达与脂质过氧化,减少血管壁脂肪堆积、丙二醛产生以及炎症介质的释放;进而改善血液的流变性,缓解了手脚冰凉、腿部肿胀、心慌等症状;3)枸杞子提取物中的枸杞多糖、人参提取物中的皂苷、杜仲叶提取物中的绿原酸共同作用,可清除自由基,增强超氧化物歧化酶和谷胱甘肽过氧化物酶活性,减少氧化应激,减轻组织损伤;刺激机体产生多种淋巴细胞因子,在体内促进免疫活性细胞的分裂增殖,提高巨噬细胞的吞噬作用及T淋巴细胞的杀伤力,进而增强机体免疫力,保护微血管结构。通过以上3方面的共同作用,使得多种作用机制互补,可较好的控制引起微循环障碍的多种危险因素,应用情况显示,本发明提供的组合物,对于微循环障碍的一般症状(头晕、头痛、失眠、胸闷、心慌、腰酸、手脚冰凉、四肢麻木、腿部肿胀、消化不良、关节痛)改善有效率高达94.5%,疗效显著,可有效预防与改善微循环障碍相关疾病;
2、本发明提供的组合物,所添加的原料均为药食两用原料,安全无副作用,可以作为预防与改善微循环障碍相关疾病的功能性食品长期食用。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。以下实施例中以1份代表1g。
实施例1
本实施例提供一种预防与改善微循环障碍相关疾病的组合物,由如下原料组分组成:地龙提取物30份、枸杞子提取物12份、人参提取物10份、杜仲叶提取物20份、桑叶提取物7份、葛根提取物21份;其中,
地龙提取物按如下方法制备得到:取地龙,50℃干燥10h、粉碎、过60目筛后,得地龙粉;向地龙粉中加入pH6.8的磷酸盐缓冲液,所述的地龙粉与磷酸盐缓冲液的重量比为1:10,于4℃冷浸12h,过滤,滤液中加入无水乙醇,滤液与无水乙醇的体积比为1:3,于4℃静置12h,过滤,滤渣干燥后,即得;
枸杞子提取物按如下方法制备得到:取枸杞子,50℃干燥24h、粉碎、过60目筛后,得枸杞子粉;向枸杞子粉中加入水,所述的枸杞子粉与水的重量比为1:30,80℃提取40min,得提取液;将提取液过滤,滤液浓缩至相对密度为0.8-1.1,得浓缩液;向浓缩液中加入无水乙醇,所述的浓缩液与无水乙醇的体积比为1:3,于4℃静置12h,过滤取上清,经冷冻干燥、过120目筛后,即得;
人参提取物按如下方法制备得到:取人参,50℃干燥12h、粉碎、过80目筛后,得人参粉;向人参粉中加入水,所述的人参粉与水的重量比为1:15,然后于沸水浴中提取1h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
杜仲叶提取物按如下方法制备得到:取杜仲叶,50℃干燥12h、粉碎、过80目筛后,得杜仲叶粉;向杜仲叶粉中加入浓度为50%v/v的乙醇,所述的杜仲叶粉与乙醇的重量比为1:10,然后于80℃提取2h,得提取液,经过滤、65℃减压浓缩、冷冻干燥、过100目筛后,即得;
桑叶提取物按如下方法制备得到:取新鲜桑叶,60℃干燥10h、粉碎、过40目筛后,得桑叶粉;向桑叶粉中加入水,所述的桑叶粉与水的重量比为1:10,然后60℃超声波提取0.5h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
葛根提取物按如下方法制备得到:取葛根,依次经清洗、破碎后,得葛根粗粒;向葛根粗粒中加入水,所述的葛根粗粒与水的重量比为1:30,然后于沸水浴中提取1h,得提取液,过滤,滤液在真空度为0.06-0.08Mpa浓缩至相对密度为1.10-1.15(70-80℃8、喷雾干燥、粉碎、过100目筛后,即得;
本实施例所述预防与改善微循环障碍相关疾病的组合物的制备方法为:分别取各原料,将所述各原料混合均匀,即得。
实施例2
本实施例提供一种预防与改善微循环障碍相关疾病的组合物,由如下原料组分组成:地龙提取物35份、枸杞子提取物10份、人参提取物12份、杜仲叶提取物16份、桑叶提取物8份、葛根提取物19份;其中,
地龙提取物按如下方法制备得到:取地龙,50℃干燥10h、粉碎、过60目筛后,得地龙粉;向地龙粉中加入pH6.8的磷酸盐缓冲液,所述的地龙粉与磷酸盐缓冲液的重量比为1:20,于4℃冷浸14h,过滤,滤液中加入无水乙醇,滤液与无水乙醇的体积比为1:3,于4℃静置12h,过滤,滤渣干燥后,即得;
枸杞子提取物按如下方法制备得到:取枸杞子,50℃干燥24h、粉碎、过60目筛后,得枸杞子粉;向枸杞子粉中加入水,所述的枸杞子粉与水的重量比为1:40,80℃提取60min,得提取液;将提取液过滤,滤液浓缩至相对密度为0.8-1.1,得浓缩液;向浓缩液中加入无水乙醇,所述的浓缩液与无水乙醇的体积比为1:5,于4℃静置12h,过滤取上清,经冷冻干燥、过120目筛后,即得;
人参提取物按如下方法制备得到:取人参,50℃干燥12h、粉碎、过80目筛后,得人参粉;向人参粉中加入水,所述的人参粉与水的重量比为1:20,然后于沸水浴中提取2h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
杜仲叶提取物按如下方法制备得到:取杜仲叶,50℃干燥12h、粉碎、过80目筛后,得杜仲叶粉;向杜仲叶粉中加入浓度为50%v/v的乙醇,所述的杜仲叶粉与乙醇的重量比为1:12,然后于90℃提取1h,得提取液,经过滤、65℃减压浓缩、冷冻干燥、过100目筛后,即得;
桑叶提取物按如下方法制备得到:取新鲜桑叶,60℃干燥10h、粉碎、过40目筛后,得桑叶粉;向桑叶粉中加入水,所述的桑叶粉与水的重量比为1:15,然后60℃超声波提取1h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
葛根提取物按如下方法制备得到:取葛根,依次经清洗、破碎后,得葛根粗粒;向葛根粗粒中加入水,所述的葛根粗粒与水的重量比为1:40,然后于沸水浴中提取2h,得提取液,过滤,滤液在真空度为0.06-0.08Mpa浓缩至相对密度为1.10-1.15(70-80℃8、喷雾干燥、粉碎、过100目筛后,即得;
本实施例所述预防与改善微循环障碍相关疾病的组合物的制备方法为:分别取各原料,将所述各原料混合均匀,即得。
实施例3
本实施例提供一种预防与改善微循环障碍相关疾病的组合物,由如下原料组分组成:地龙提取物40份、枸杞子提取物8份、人参提取物14份、杜仲叶提取物12份、桑叶提取物9份、葛根提取物17份;其中,
地龙提取物按如下方法制备得到:取地龙,50℃干燥10h、粉碎、过60目筛后,得地龙粉;向地龙粉中加入pH6.8的磷酸盐缓冲液,所述的地龙粉与磷酸盐缓冲液的重量比为1:15,于4℃冷浸13h,过滤,滤液中加入无水乙醇,滤液与无水乙醇的体积比为1:3,于4℃静置12h,过滤,滤渣干燥后,即得;
枸杞子提取物按如下方法制备得到:取枸杞子,50℃干燥24h、粉碎、过60目筛后,得枸杞子粉;向枸杞子粉中加入水,所述的枸杞子粉与水的重量比为1:35,80℃提取50min,得提取液;将提取液过滤,滤液浓缩至相对密度为0.8-1.1,得浓缩液;向浓缩液中加入无水乙醇,所述的浓缩液与无水乙醇的体积比为1:4,于4℃静置12h,过滤取上清,经冷冻干燥、过120目筛后,即得;
人参提取物按如下方法制备得到:取人参,50℃干燥12h、粉碎、过80目筛后,得人参粉;向人参粉中加入水,所述的人参粉与水的重量比为1:18,然后于沸水浴中提取1.5h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
杜仲叶提取物按如下方法制备得到:取杜仲叶,50℃干燥12h、粉碎、过80目筛后,得杜仲叶粉;向杜仲叶粉中加入浓度为50%v/v的乙醇,所述的杜仲叶粉与乙醇的重量比为1:10,然后于90℃提取1.5h,得提取液,经过滤、65℃减压浓缩、冷冻干燥、过100目筛后,即得;
桑叶提取物按如下方法制备得到:取新鲜桑叶,60℃干燥10h、粉碎、过40目筛后,得桑叶粉;向桑叶粉中加入水,所述的桑叶粉与水的重量比为1:12,然后60℃超声波提取1h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
葛根提取物按如下方法制备得到:取葛根,依次经清洗、破碎后,得葛根粗粒;向葛根粗粒中加入水,所述的葛根粗粒与水的重量比为1:35,然后于沸水浴中提取1.5h,得提取液,过滤,滤液在真空度为0.06-0.08Mpa浓缩至相对密度为1.10-1.15(70-80℃8、喷雾干燥、粉碎、过100目筛后,即得;
本实施例所述预防与改善微循环障碍相关疾病的组合物的制备方法为:分别取各原料,将所述各原料混合均匀,即得。
实施例4
本实施例提供一种预防与改善微循环障碍相关疾病的组合物,由如下原料组分组成:地龙提取物45份、枸杞子提取物6份、人参提取物16份、杜仲叶提取物10份、桑叶提取物10份、葛根提取物13份;其中,
地龙提取物按如下方法制备得到:取地龙,50℃干燥10h、粉碎、过60目筛后,得地龙粉;向地龙粉中加入pH6.8的磷酸盐缓冲液,所述的地龙粉与磷酸盐缓冲液的重量比为1:15,于4℃冷浸13h,过滤,滤液中加入无水乙醇,滤液与无水乙醇的体积比为1:3,于4℃静置12h,过滤,滤渣干燥后,即得;
枸杞子提取物按如下方法制备得到:取枸杞子,50℃干燥24h、粉碎、过60目筛后,得枸杞子粉;向枸杞子粉中加入水,所述的枸杞子粉与水的重量比为1:35,80℃提取50min,得提取液;将提取液过滤,滤液浓缩至相对密度为0.8-1.1,得浓缩液;向浓缩液中加入无水乙醇,所述的浓缩液与无水乙醇的体积比为1:4,于4℃静置12h,过滤取上清,经冷冻干燥、过120目筛后,即得;
人参提取物按如下方法制备得到:取人参,50℃干燥12h、粉碎、过80目筛后,得人参粉;向人参粉中加入水,所述的人参粉与水的重量比为1:18,然后于沸水浴中提取1.5h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
杜仲叶提取物按如下方法制备得到:取杜仲叶,50℃干燥12h、粉碎、过80目筛后,得杜仲叶粉;向杜仲叶粉中加入浓度为50%v/v的乙醇,所述的杜仲叶粉与乙醇的重量比为1:10,然后于90℃提取1.5h,得提取液,经过滤、65℃减压浓缩、冷冻干燥、过100目筛后,即得;
桑叶提取物按如下方法制备得到:取新鲜桑叶,60℃干燥10h、粉碎、过40目筛后,得桑叶粉;向桑叶粉中加入水,所述的桑叶粉与水的重量比为1:12,然后60℃超声波提取1h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
葛根提取物按如下方法制备得到:取葛根,依次经清洗、破碎后,得葛根粗粒;向葛根粗粒中加入水,所述的葛根粗粒与水的重量比为1:35,然后于沸水浴中提取1.5h,得提取液,过滤,滤液在真空度为0.06-0.08Mpa浓缩至相对密度为1.10-1.15(70-80℃8、喷雾干燥、粉碎、过100目筛后,即得;
本实施例所述预防与改善微循环障碍相关疾病的组合物的制备方法为:分别取各原料,将所述各原料混合均匀,即得。
实施例5
本实施例提供一种预防与改善微循环障碍相关疾病的组合物,由如下原料组分组成:地龙提取物50份、枸杞子提取物4份、人参提取物20份、杜仲叶提取物8份、桑叶提取物11份、葛根提取物7份;其中,
地龙提取物按如下方法制备得到:取地龙,50℃干燥10h、粉碎、过60目筛后,得地龙粉;向地龙粉中加入pH6.8的磷酸盐缓冲液,所述的地龙粉与磷酸盐缓冲液的重量比为1:15,于4℃冷浸13h,过滤,滤液中加入无水乙醇,滤液与无水乙醇的体积比为1:3,于4℃静置12h,过滤,滤渣干燥后,即得;
枸杞子提取物按如下方法制备得到:取枸杞子,50℃干燥24h、粉碎、过60目筛后,得枸杞子粉;向枸杞子粉中加入水,所述的枸杞子粉与水的重量比为1:35,80℃提取50min,得提取液;将提取液过滤,滤液浓缩至相对密度为0.8-1.1,得浓缩液;向浓缩液中加入无水乙醇,所述的浓缩液与无水乙醇的体积比为1:4,于4℃静置12h,过滤取上清,经冷冻干燥、过120目筛后,即得;
人参提取物按如下方法制备得到:取人参,50℃干燥12h、粉碎、过80目筛后,得人参粉;向人参粉中加入水,所述的人参粉与水的重量比为1:18,然后于沸水浴中提取1.5h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
杜仲叶提取物按如下方法制备得到:取杜仲叶,50℃干燥12h、粉碎、过80目筛后,得杜仲叶粉;向杜仲叶粉中加入浓度为50%v/v的乙醇,所述的杜仲叶粉与乙醇的重量比为1:10,然后于90℃提取1.5h,得提取液,经过滤、65℃减压浓缩、冷冻干燥、过100目筛后,即得;
桑叶提取物按如下方法制备得到:取新鲜桑叶,60℃干燥10h、粉碎、过40目筛后,得桑叶粉;向桑叶粉中加入水,所述的桑叶粉与水的重量比为1:12,然后60℃超声波提取1h,得提取液,经过滤、浓缩、冷冻干燥、过100目筛后,即得;
葛根提取物按如下方法制备得到:取葛根,依次经清洗、破碎后,得葛根粗粒;向葛根粗粒中加入水,所述的葛根粗粒与水的重量比为1:35,然后于沸水浴中提取1.5h,得提取液,过滤,滤液在真空度为0.06-0.08Mpa浓缩至相对密度为1.10-1.15(70-80℃8、喷雾干燥、粉碎、过100目筛后,即得;
本实施例所述预防与改善微循环障碍相关疾病的组合物的制备方法为:分别取各原料,将所述各原料混合均匀,即得。
经检测,以上各实施例制备的地龙提取物的蛋白含量≥26%;人参提取物的人参皂苷含量为2.5-3%、多糖含量为10-12%;杜仲叶提取物的绿原酸含量为3.9-4.2%;葛根提取物的葛根素含量为10-12%。
对比例1
与实施例3的区别仅在于原料组成不同,本对比例由如下原料组分组成:地龙提取物40份、枸杞子提取物25份、人参提取物14份、杜仲叶提取物12份、桑叶提取物9份。
对比例2
与实施例3的区别仅在于原料组成不同,本对比例由如下原料组分组成:枸杞子提取物48份、人参提取物14份、杜仲叶提取物12份、桑叶提取物9份、葛根提取物17份。
对比例3
与实施例3的区别仅在于原料组成不同,本对比例由如下原料组分组成:地龙提取物40份、枸杞子提取物22份、杜仲叶提取物12份、桑叶提取物9份、葛根提取物17份。
试验例
征集有微循环障碍的一般症状(头晕、头痛、失眠、胸闷、心慌、腰酸、手脚冰凉、四肢麻木、腿部肿胀、消化不良、关节痛中至少有一项者)志愿者200人,年龄在30-75岁之间,男性120人,女性80人,随机分为4组,分别为试验组、对照组一、对照组二和对照组三,试验组55人,对照组一47人,对照组二48人,对照组三50人。试验组志愿者食用实施例3得到的组合物,每天2次,每次1袋,10g/袋;对照组一志愿者食用对比例1得到的组合物,每天2次,每次1袋,10g/袋;对照组二志愿者食用对比例2得到的组合物,每天2次,每次1袋,10g/袋;对照组三志愿者食用对比例3得到的组合物,每天2次,每次1袋,10g/袋;各组连续食用6个月,对各组志愿者进行检查记录,统计结果,结果见表1。
评价效果的标准为:
显效:头晕、头痛、失眠、胸闷、心慌、腰酸、手脚冰凉、四肢麻木、腿部肿胀、消化不良、关节痛11种主要临床症状有1种以上改善,且无其他不良反应;
无效:头晕、头痛、失眠、胸闷、心慌、腰酸、手脚冰凉、四肢麻木、腿部肿胀、消化不良、关节痛11种主要临床症状均没有改善,或者是有不良反应;
有效率为显效与每组总人数的百分比。
表1试验结果
组别 | 显效(人) | 无效(人) | 有效率(%) |
试验组 | 52 | 3 | 94.5% |
对照组一 | 42 | 5 | 89.4% |
对照组二 | 35 | 13 | 72.9% |
对照组三 | 40 | 10 | 80% |
从表1的结果可以看出,本发明提供的组合物对微循环障碍人群的一般症状具有明显的改善作用,而各对照组功效远远不及试验组的效果,与对照组一相比,试验组的有效率提高5.1%,与对照组二相比,试验组的有效率提高21.6%,与对照组三相比,试验组的有效率提高14.5%,效果显著。且试验中显示,手脚冰凉、四肢麻木的改善尤为突出,占有效人数的67.3%。以上结果说明了,本发明提供的组合物原料配比合理,各组分相互配合,能够协同提高其在预防与改善微循环障碍相关疾病方面的效果。
典型案例
樊某,女,33岁,手脚冰凉、失眠、贫血,服用本发明实施例3的组合物,每天早晚各1袋,连续服用15天之后,手脚冰凉得到改善,继续服用30天,脸色红润,失眠得到改善,睡眠时间由之前的4-5小时增加到6-7小时,失眠间隔时间与次数减少。
王某,女,42岁,血脂高、睡眠质量差、消化不良、易感冒,服用本发明实施例2的组合物,每天早晚各1袋,服用10天,睡眠质量改善,起床后的头晕感消失。继续服用28天,腹胀感消失,返酸次数减少,面色红润,感冒次数减少。
李某,男,66岁,高血压、血脂高、腿部静脉曲张,时常伴有胸闷,服用本发明实施例3的组合物,每天早晚各1袋,服用14天,胸闷感减弱,腿部肿胀感减弱。继续服用30天,血压降低了2mmHg,睡眠时间增加了1小时。继续服用3个月,胸闷感消失,面色红润,整个人很有精神。
赵某,男,52岁,血糖高、颈动脉有斑块、伴有头晕,服用本发明实施例5的组合物,每天早晚各1袋,服用7天,头晕感消失,人也精神了。继续服用30天,血糖处于平稳状态,腿部浮肿也消失。接着服用2个月,颈动脉的斑块体积减小,睡眠质量改善。
5、郝某,女,67岁,乏力、胸闷、形体偏瘦,服用本发明实施例4的组合物,每天早晚各1袋,服用7天,乏力感消失,食欲增强,腰酸缓解。继续服用30天,胸闷得到改善,整个人精神了,体重略有增加。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (10)
1.一种预防与改善微循环障碍相关疾病的组合物,其特征在于,包括如下原料组分:
地龙提取物30-50份、枸杞子提取物4-12份、人参提取物10-20份、杜仲叶提取物8-20份、桑叶提取物7-11份、葛根提取物7-21份。
2.根据权利要求1所述预防与改善微循环障碍相关疾病的组合物,其特征在于,包括如下原料组分:
地龙提取物35-45份、枸杞子提取物6-10份、人参提取物12-16份、杜仲叶提取物10-16份、桑叶提取物8-10份、葛根提取物13-19份。
3.根据权利要求1所述预防与改善微循环障碍相关疾病的组合物,其特征在于,包括如下原料组分:
地龙提取物40份、枸杞子提取物8份、人参提取物14份、杜仲叶提取物12份、桑叶提取物9份、葛根提取物17份。
4.根据权利要求1所述预防与改善微循环障碍相关疾病的组合物,其特征在于,所述地龙提取物的蛋白含量不低于26%;所述人参提取物的人参皂苷含量为2.5-3%、多糖含量为10-12%;所述杜仲叶提取物的绿原酸含量为3.9-4.2%;所述葛根提取物的葛根素含量为10-12%。
5.根据权利要求1-4之一所述预防与改善微循环障碍相关疾病的组合物,其特征在于,所述地龙提取物按如下方法制备得到:
取地龙,依次经干燥、粉碎、过筛后,得地龙粉;向地龙粉中加入pH6.8的磷酸盐缓冲液,所述的地龙粉与磷酸盐缓冲液的重量比为1:10-20,于4℃冷浸12-14h,过滤,滤液中加入无水乙醇,滤液与无水乙醇的体积比为1:3,于4℃静置12h,过滤,滤渣干燥后,即得。
6.根据权利要求1-4之一所述预防与改善微循环障碍相关疾病的组合物,其特征在于,所述枸杞子提取物、人参提取物、桑叶提取物、葛根提取物分别为枸杞子、人参、桑叶以及葛根的水提取物,所述的杜仲叶提取物为杜仲叶的醇提取物。
7.根据权利要求6所述预防与改善微循环障碍相关疾病的组合物,其特征在于,所述枸杞子提取物按如下方法制备得到:取枸杞子,依次经干燥、粉碎、过筛后,得枸杞子粉;向枸杞子粉中加入水,所述的枸杞子粉与水的重量比为1:30-40,80℃提取40-60min,得提取液;将提取液过滤,滤液浓缩至相对密度为0.8-1.1,得浓缩液;向浓缩液中加入无水乙醇,所述的浓缩液与无水乙醇的体积比为1:3-5,于4℃静置12h,过滤取上清,经冷冻干燥、过筛后,即得;
和/或,所述人参提取物按如下方法制备得到:取人参,依次经干燥、粉碎、过筛后,得人参粉;向人参粉中加入水,所述的人参粉与水的重量比为1:15-20,然后于沸水浴中提取1-2h,得提取液,经过滤、浓缩、冷冻干燥、过筛后,即得;
和/或,所述杜仲叶提取物按如下方法制备得到:取杜仲叶,依次经干燥、粉碎、过筛后,得杜仲叶粉;向杜仲叶粉中加入浓度为50%v/v的乙醇,所述的杜仲叶粉与乙醇的重量比为1:10-12,然后于80-90℃提取1-2h,得提取液,经过滤、浓缩、冷冻干燥、过筛后,即得;
和/或,所述桑叶提取物按如下方法制备得到:取新鲜桑叶,依次经干燥、粉碎、过筛后,得桑叶粉;向桑叶粉中加入水,所述的桑叶粉与水的重量比为1:10-15,然后60℃超声波提取0.5-1h,得提取液,经过滤、浓缩、冷冻干燥、过筛后,即得;
和/或,所述葛根提取物按如下方法制备得到:取葛根,依次经清洗、破碎后,得葛根粗粒;向葛根粗粒中加入水,所述的葛根粗粒与水的重量比为1:30-40,然后于沸水浴中提取1-2h,得提取液,经过滤、浓缩、喷雾干燥、过筛后,即得。
8.权利要求1-7之一所述预防与改善微循环障碍相关疾病的组合物的制备方法,其特征在于,具体步骤为:分别取各原料,将所述各原料混合均匀,即得。
9.权利要求1-7之一所述预防与改善微循环障碍相关疾病的组合物在制备预防与改善微循环障碍相关疾病的保健食品或药品中的应用。
10.根据权利要求9所述的应用,所述微循环障碍相关疾病的症状包括头晕、头痛、失眠、胸闷、心慌、腰酸、手脚冰凉、四肢麻木、腿部肿胀、消化不良、关节痛中的任意一种或几种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211179904.6A CN115428952A (zh) | 2022-09-27 | 2022-09-27 | 预防与改善微循环障碍相关疾病的组合物、其制法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211179904.6A CN115428952A (zh) | 2022-09-27 | 2022-09-27 | 预防与改善微循环障碍相关疾病的组合物、其制法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115428952A true CN115428952A (zh) | 2022-12-06 |
Family
ID=84249096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211179904.6A Pending CN115428952A (zh) | 2022-09-27 | 2022-09-27 | 预防与改善微循环障碍相关疾病的组合物、其制法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115428952A (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1602926A (zh) * | 2004-08-09 | 2005-04-06 | 汪卫东 | 可调节血压和血脂、防治心脑血管疾病的葛胶囊 |
CN101914472A (zh) * | 2010-07-27 | 2010-12-15 | 灵宝上洋科技有限责任公司 | 一种杜仲叶提取物及其制备方法和应用 |
CN102038743A (zh) * | 2009-10-13 | 2011-05-04 | 陈洁 | 新型抑制心血管植物提取物及提取方法和应用 |
CN103830436A (zh) * | 2014-03-07 | 2014-06-04 | 大连圣弘医药有限公司 | 治疗高血压的中药组合物及其制备方法 |
CN104208654A (zh) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | 一种以地龙蛋白提取物为主的保健配方 |
CN107308051A (zh) * | 2017-07-07 | 2017-11-03 | 平利县绞股蓝研究所 | 绞股蓝液、含绞股蓝液的混合物、制备方法及应用 |
CN107484930A (zh) * | 2017-08-24 | 2017-12-19 | 贵州健瑞安药业有限公司 | 预防心脑血管疾病饮品及其制备方法 |
CN113209153A (zh) * | 2021-04-30 | 2021-08-06 | 江西普正制药股份有限公司 | 一种杜仲组合物、制备方法及其应用 |
CN113521243A (zh) * | 2021-09-07 | 2021-10-22 | 李东泽 | 一种改善人体微循环的中药组合物及制备方法 |
CN114224934A (zh) * | 2021-12-29 | 2022-03-25 | 国际遗传工程和生物技术中心泰州区域研究中心 | 一种改善微循环的杜仲提取物 |
CN115040612A (zh) * | 2022-07-11 | 2022-09-13 | 陈淼娟 | 一种调理高血压的组合物及其制备方法 |
-
2022
- 2022-09-27 CN CN202211179904.6A patent/CN115428952A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1602926A (zh) * | 2004-08-09 | 2005-04-06 | 汪卫东 | 可调节血压和血脂、防治心脑血管疾病的葛胶囊 |
CN102038743A (zh) * | 2009-10-13 | 2011-05-04 | 陈洁 | 新型抑制心血管植物提取物及提取方法和应用 |
CN101914472A (zh) * | 2010-07-27 | 2010-12-15 | 灵宝上洋科技有限责任公司 | 一种杜仲叶提取物及其制备方法和应用 |
CN103830436A (zh) * | 2014-03-07 | 2014-06-04 | 大连圣弘医药有限公司 | 治疗高血压的中药组合物及其制备方法 |
CN104208654A (zh) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | 一种以地龙蛋白提取物为主的保健配方 |
CN107308051A (zh) * | 2017-07-07 | 2017-11-03 | 平利县绞股蓝研究所 | 绞股蓝液、含绞股蓝液的混合物、制备方法及应用 |
CN107484930A (zh) * | 2017-08-24 | 2017-12-19 | 贵州健瑞安药业有限公司 | 预防心脑血管疾病饮品及其制备方法 |
CN113209153A (zh) * | 2021-04-30 | 2021-08-06 | 江西普正制药股份有限公司 | 一种杜仲组合物、制备方法及其应用 |
CN113521243A (zh) * | 2021-09-07 | 2021-10-22 | 李东泽 | 一种改善人体微循环的中药组合物及制备方法 |
CN114224934A (zh) * | 2021-12-29 | 2022-03-25 | 国际遗传工程和生物技术中心泰州区域研究中心 | 一种改善微循环的杜仲提取物 |
CN115040612A (zh) * | 2022-07-11 | 2022-09-13 | 陈淼娟 | 一种调理高血压的组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100998225B1 (ko) | 녹용, 산수유, 당귀, 구기자, 산약, 진피, 천마, 배초향, 계피, 홍삼, 및 오미자의 추출물을 유효성분으로 포함하는 면역증강 조성물 | |
CN102511869B (zh) | 红枣生姜浓浆 | |
CN101317615B (zh) | 一种银棘茶饮料及其制备方法 | |
CN103416625A (zh) | 一种大麦型仔猪饲料及其制备方法 | |
CN106562413A (zh) | 一种提高免疫力膏滋及其制备方法 | |
CN101612315A (zh) | 一种用于调整人体机能的中药复方制剂 | |
CN105695258A (zh) | 一种含荔枝核皂苷的女性保健酒 | |
CN111264735A (zh) | 一种扶正固本提高免疫力防控疫毒的功能饮料 | |
KR20210063657A (ko) | 헛개나무 추출물 및 백년초 분말을 함유한 숙취해소용 천연차 및 그 제조방법 | |
CN113855766A (zh) | 一种可调理血压的银杏蛹虫草冲剂 | |
CN117599140A (zh) | 一种降血糖、降血压、降血脂的中药组合物及其制备与应用 | |
CN102090637A (zh) | 一种含有胶原蛋白的复方营养粉 | |
CN111249410A (zh) | 一种保肝解毒排脂防治肝损伤恢复肝功能的药膳饮料 | |
CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
CN105981853A (zh) | 一种营养功能丰富的温和的暖茶饮料配方 | |
KR101227063B1 (ko) | 혈액순환 개선용 식품 조성물 및 그 제조방법 | |
CN115428952A (zh) | 预防与改善微循环障碍相关疾病的组合物、其制法及应用 | |
CN1314423C (zh) | 可调节血压和血脂、防治心脑血管疾病的葛胶囊 | |
CN106942561A (zh) | 一种饮料组合物及其制备方法与应用 | |
KR20190029971A (ko) | 관상동맥성 심장질환의 예방과 치료용 생약조성물 | |
KR20030053417A (ko) | 삼백초를 주성분으로 한 건강식품 | |
CN114129611A (zh) | 一种预防与改善肝脏炎症疾病的组合物及制备方法 | |
CN113875864A (zh) | 一种降血糖抑糖茶及其制备方法 | |
CN112076305A (zh) | 一种治疗人体代谢症候群及杀菌消炎的中药制内服外用原液合剂 | |
CN110679935A (zh) | 一种牛蒡人参精华膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221206 |